Precision, Personalization, & Partnerships

From the cutting-edge discussions set to unfold at Davos 2024 to valuable insights of year-end conferences, this edition is packed with news of exciting partnerships, progress in precision psychiatry, neuroscience impacting personalized marketing, and promising strides in alternative therapies. We hope you enjoy the read and our team at Convergence wishes you a wonderful festive season!

Top 3 Highlights:

Applications are open for our Davos 2024 event

Calling all mental health innovation enthusiasts! Join us in Davos at the House of Trust event during the World Economic Forum to hear from a panel of experts coming from academia, venture, the public sector, and from the frontlines of innovation - entrepreneurs. This event will also showcase the launch of the AguilaCondor Foundation which aims to bridge two paradigms - the knowledge preserved by indigenous communities and the western medical model.

Read More: Here

Top 5 Insights from the SuperInvestor Conference by Daniel Koppelkamm, CFA

Daniel Koppelkamm, CFA , managing partner at Convergence Partners joined over 1500 decision makers at the SuperInvestor conference in Zurich. Along with other panelist, he lead a discussion on "When impact goes wrong: the increase in regulation and litigation" and also spoke about the importance and progress happening in the +$500 billion Brain Health market. We summarized Dan's Top 5 in the link below!

Read More: Here

Neuromarketing or Manipulation?

Neuromarketing, friend or foe? This eye-opening article written by Michelle Tempest and Poran Malani brings to light the power of neuromarketing beyond the context of political propaganda. By analyzing brain responses to brands through techniques like fMRI and EEG, neuromarketing uncovers hidden consumer preferences. The authors cover the more known negative effects of neuromarketing but also the possible positive implications such as promoting healthier habits.

Read More: Here

Other Notable News Items:

• Biomarkers & Stratified Psychiatry: Published by Martijn Arns , an advisor with our Brain Health Fund, argues that stratified psychiatry could be a pragmatic treatment alternative for mental health disorders. Read more.
• Boston Scientific acquires Relievant Medsystems, Inc. for $850 million: The is expected to expand patient access to the Intracept system through national coverage from major health insurers. Read more.
• Potential in Slowing Neurodegeneration: Promising results from Cognito Therapeutics, Inc. Phase II clinical trials shows a slow down in white matter atrophy in Alzheimer's patients. Read more.
• Neuralink Raises Another $43 million: Elon Musk's venture has increased its total capital raised from $280 million to $323 million. Read more.
• Propelling Precision Psychiatry: Our portfolio company, Clerkenwell Health , has partnered with Brainify.AI in a collaboration to revolutionize the psychiatric clinical trial landscape. Read more.
• Investing into Speech-Based Monitoring, Schizophrenia: French start-up, Callyope , has raised $2.4 million. Callyope enables psychiatrists to deliver remote personalized and outcome-based care. Read more.
• Psychedelics & AI: The article, co-authored by Anne Philippi , examines the intriguing relationship between AI and psychedelics, suggesting that this combination could lead to significant advancements in mental health care and treatment. Read More.

Your Monthly Source on Brain Health

We hope you enjoyed the read! Join our newsletter list to receive your monthly updates on Brain Health. Let's tackle the Brain Health mission together. ??